Researchers from Quest Diagnostics and Hologic analyzed laboratory data from 2022 to 2024, revealing that 38.7% of the women studied tested positive for bacterial vaginosis (BV). Among this group, 12% were co-infected with at least one STI, a stark contrast to the 3.8% infection rate found in BV-negative patients. The study, published in O&G Open, highlights that while BV is a common health issue, it serves as a critical indicator for broader diagnostic screening.
Adjusted data shows that a BV-positive status correlates with significantly higher odds for specific infections: 2.8 times higher for Chlamydia trachomatis, 3.8 times for Neisseria gonorrhoeae, and 3.6 times for Trichomonas vaginalis. By comparison, the presence of vulvovaginal candidiasis showed no association with increased STI risk. Dr. Damian P. Alagia III, a senior medical director at Quest, noted that these findings support current CDC guidelines, which advocate for comprehensive STI testing when BV is present. Modern molecular diagnostics now allow clinicians to identify these co-infections from a single specimen, streamlining care for patients who might otherwise remain undiagnosed.

Comments (0)
No comments yet. Be the first!